Streetbeat News

Analyst Ratings

MMSI

Merit Medical Systems (NASDAQ:MMSI) received varied analyst ratings in the last quarter, with an average 12-month price target of $93.00, up from the previous $88.75. Analysts from Piper Sandler, Canaccord Genuity, Barrington Research, and Needham have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Merit Medical Systems, a medical equipment company, shows strong financial health with a positive revenue trend, high net margin, and efficient debt management, despite lagging behind industry peers in revenue growth.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 4:01 pm

FIVN

Five9 (NASDAQ:FIVN) has received diverse analyst ratings over the past three months, with 11 analysts offering opinions ranging from bullish to bearish. The average 12-month price target is $88.45, with a high of $100.00 and a low of $77.00, marking a 2.27% decrease from the previous average. Analysts have adjusted their ratings and price targets, with some maintaining and others raising or lowering their stance. Five9's financial performance shows a revenue growth of 16.01% but trails behind industry peers, with a net margin of -8.87%, ROE of -4.29%, ROA of -1.43%, and a high debt-to-equity ratio of 1.61.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 4:00 pm

COO

Analysts have provided mixed reviews on Cooper Companies (NASDAQ:COO) with 4 different ratings over the past quarter. The average 12-month price target is now $387.5, down 5.1% from the previous $408.33. Piper Sandler's Jason Bednar raised the target to $440, Morgan Stanley's Patrick Wood and JP Morgan's Robbie Marcus lowered their targets to $355 and $375 respectively, and B of A Securities' Craig Bijou set a target of $380. Cooper Companies operates in eye care and women's healthcare, showing strong financial performance with a 9.31% revenue growth, a net margin of 9.11%, and a ROE of 1.12%.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 4:00 pm

DOCU

Eight analysts have recently published ratings on DocuSign (NASDAQ:DOCU), with a mix of opinions ranging from bullish to bearish. Over the past three months, sentiments have shifted, with the current distribution showing 2 somewhat bullish, 4 indifferent, and 2 somewhat bearish ratings. The 12-month price targets have an average of $54.38, with a high of $84.00 and a low of $45.00. Several analysts have maintained their ratings, while others have lowered their price targets. DocuSign's financial performance shows strong revenue growth and net margin but lags in ROE compared to industry averages. The company's market capitalization is below industry averages, and it has a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 4:00 pm

RNG

Piper Sandler analyst James Fish has maintained a Neutral rating on RingCentral (NYSE:RNG) and increased the price target from $32 to $34.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:53 pm

MMSI

Piper Sandler analyst Jason Bednar has maintained an Overweight rating on Merit Medical Systems (NASDAQ:MMSI) and increased the price target from $88 to $95.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:52 pm

HRL

Piper Sandler analyst Michael Lavery has maintained a Neutral rating on Hormel Foods (NYSE:HRL) and increased the price target from $31 to $33.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:50 pm

BAC

JPM

XLF

JPMorgan Chase & Co (JPM) and Bank of America Corp (BAC) reported Q4 2023 earnings, with JPM outperforming BAC. JPM benefited from new deposits, a low-cost acquisition, and record profits, while BAC faced challenges due to interest rate sensitivity and unrealized losses on long-term securities. With expected rate cuts in 2024, analysts see more upside in BAC stock (11.58%) than JPM (9.66%), despite BAC's risks. The Financial Select Sector SPDR Fund (XLF) gained over 5% in 2023.

Portfolio Pulse from Surbhi Jain

January 12, 2024 | 3:48 pm

FIVN

Piper Sandler analyst James Fish has maintained an Overweight rating on Five9 (NASDAQ:FIVN) and increased the price target from $84 to $86.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:48 pm

FFNW

Piper Sandler analyst Andrew Liesch has maintained an Overweight rating on First Financial Northwest (NASDAQ: FFNW) and increased the price target from $14 to $23.5.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:46 pm